| scholarly article | Q13442814 |
| P2093 | author name string | Brian B Gowen | |
| Amanda Mathis | |||
| William P Sheridan | |||
| Jonna B Westover | |||
| Kevin W Bailey | |||
| Eric J Sefing | |||
| Kie-Hoon Jung | |||
| Brady T Hickerson | |||
| Ray Taylor | |||
| Luci Wandersee | |||
| P2860 | cites work | In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections | Q27481401 |
| Rift Valley fever virus infection in golden Syrian hamsters | Q28543047 | ||
| Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses | Q29365262 | ||
| Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model | Q30395163 | ||
| Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. | Q34040052 | ||
| BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model | Q34041804 | ||
| The pathogenesis of Rift Valley fever | Q34191969 | ||
| Rift Valley fever virus | Q34971963 | ||
| Development of a novel nonhuman primate model for Rift Valley fever | Q35826546 | ||
| BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease | Q37077376 | ||
| Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets | Q37547173 | ||
| Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment | Q37683496 | ||
| One Health approach to Rift Valley fever vaccine development | Q38200401 | ||
| Quantifying the potential pathways and locations of Rift Valley fever virus entry into the United States. | Q38964465 | ||
| Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. | Q40308414 | ||
| Potential for North American mosquitoes to transmit Rift Valley fever virus | Q40398345 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Rift Valley fever | Q326638 |
| Rift Valley fever virus | Q14276794 | ||
| P304 | page(s) | 38-45 | |
| P577 | publication date | 2018-08-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters | |
| P478 | volume | 156 |
| Q64359221 | An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice |
| Q89795210 | Antivirals in medical biodefense |
| Q99401090 | COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy |
| Q95630795 | Chemistry and Biology of SARS-CoV-2 |
| Q98626411 | Emerging strategies on in silico drug development against COVID-19: challenges and opportunities |
| Q90419101 | Importance of Zika Virus NS5 Protein for Viral Replication |
| Q66678817 | Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir |
| Q92471636 | New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections |
| Q100384122 | Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review |
| Q108084285 | RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic |
Search more.